- Home
- CAC vs GHRS Comparison
CAC vs GHRS Comparison
Compare CAC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAC | GHRS |
|---|---|---|
| Founded | 1875 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 857.1M | 947.2M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CAC | GHRS |
|---|---|---|
| Price | $50.51 | $20.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $47.00 | $41.38 |
| AVG Volume (30 Days) | 79.1K | ★ 223.4K |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 6.08 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $41,739,000.00 | N/A |
| Revenue This Year | $19.15 | N/A |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | $39.15 | ★ N/A |
| Revenue Growth | ★ 16.96 | N/A |
| 52 Week Low | $35.00 | $11.32 |
| 52 Week High | $53.71 | $25.94 |
Technical Indicators
Market Signals| Indicator | CAC | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 45.62 |
| Support Level | $47.12 | $12.65 |
| Resistance Level | $51.47 | $22.88 |
| Average True Range (ATR) | 1.54 | 1.65 |
| MACD | 0.16 | -0.33 |
| Stochastic Oscillator | 90.46 | 5.78 |
Price Performance
Historical ComparisonAbout CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.